Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

NCT04697953 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study terminated - no participants were enrolled.

Conditions

Age-related Macular Degeneration (AMD)

Interventions

DRUG: brolucizumab

Sponsor

Novartis Pharmaceuticals